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Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has
become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical
trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have
excluded patients with underlying autoimmune disease given concern for potential triggering of autoimmune
exacerbations. We present the first known cases to our knowledge of two patients with active autoimmune diseases
who received ipilimumab. In this limited clinical experience, no serious exacerbations of underlying autoimmunity
have yet been observed, and one patient benefited from ipilimumab. These cases advocate for further investigation
of the safety of cancer immunotherapies in cancer patients with underlying autoimmune conditions in carefully
designed clinical trials with cautious monitoring.
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Cytotoxic T-lymphocyte antigen 4 (CTLA-4), an immune-
checkpoint receptor and regulator of T-cell activation, has
become an important therapeutic target for immunother-
apy in cancer. Ipilimumab, a fully human antibody that
blocks CTLA-4, was the first immunomodulatory check-
point inhibitor approved by the United States Food and
Drug Administration (FDA) for patients with advanced
melanoma [1,2]. Treatment with ipilimumab can be asso-
ciated with inflammatory side effects, termed “immune-
related adverse events” (irAEs) [3,4].
Given the critical role of CTLA-4 in maintaining
immunologic homeostasis, clinical trials involving ipi-
limumab and cancer immunotherapies in general have
excluded patients with underlying autoimmune diseases
out of concern for triggering autoimmune exacerbations
in these individuals. In preclinical models, anti-CTLA-4
treatment is known to enhance onset and severity of sev-
eral T cell-mediated experimental autoimmune diseases,
including murine models of encephalomyelitis [5,6], myas-
thenia gravis [7], and type 1 diabetes [8]. Yet, the clinical* Correspondence: postowm@mskcc.org
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unless otherwise stated.experience treating patients with ipilimumab who have
advanced melanoma and concomitant, underlying auto-
immune diseases has not been described.
We report two patients with advanced melanoma and
a concomitant autoimmune disorder who were treated
with ipilimumab; one had multiple sclerosis and another
had rheumatoid arthritis. Ipilimumab was well tolerated
in both patients without related exacerbation of their
known autoimmune disease. One patient had a profound
anti-tumor effect from ipilimumab.Case presentation 1
A 52-year-old man was diagnosed in March 2010 with
multiple sclerosis (MS) when he presented to a neurolo-
gist with episodes of fatigue, lower extremity paresthe-
sias, and bowel and bladder incontinence. The diagnosis
of MS was made based upon the McDonald criteria with
multiple clinical events associated with characteristic
imaging findings [9]. He received initial treatment with
glatiramer 20 mg daily via subcutaneous injection (an
immunomodulatory drug that activates regulatory T-
lymphocyte suppressor cells) and dalfampridine 20 mg
twice daily orally (a potassium channel blocker affecting
nerve conduction). After a year of treatment, he then
received interferon beta 44mcg three times weekly viaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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relapsing-remitting subtype, was active as he had suffered
flares associated with increased weakness once every few
months, requiring hospitalization and subsequent rehabili-
tation. Nonetheless, he was fully ambulatory and inde-
pendent with his activities of daily living.
The patient’s melanoma history began shortly after
initiation of treatment for MS when the patient first noted
a lump on his right lower back. Shave biopsy revealed inva-
sive, ulcerated melanoma to a depth of at least 3.5 mm
Breslow thickness. He then underwent a wide excision and
sentinel lymph node biopsy. Sentinel lymph node biopsy
revealed micrometastatic disease in one lymph node in the
right axilla, and a separate lymph node with melanoma
was involved in the right inguinal region. Molecular
analysis showed no detectable BRAF V600 mutation. After
extensive discussion of options, the patient elected a pro-
gram of vigilant observation rather than complete lymph
node dissection of the two involved lymph node basins.
Interferon alpha was discussed, but due to the patient’s
active multiple sclerosis, he was thought not to be a good
candidate for aggressive adjuvant therapy.
Nine months after wide excision, patient’s cancer
recurred as multiple skin nodules involving his right flank,
as well as right groin and right axilla lymphadenopathy.
Excisional biopsy of a right groin nodule revealed meta-
static melanoma. He was treated initially with temo-
zolomide 75 mg/m2 daily in an extended dosing regimen
[10]. After one month, a computed tomography (CT) scan
showed evidence of disease progression with worsening
lymphadenopathy, as well as progressive subcutaneous
lesions on his right flank.
Due to limited treatment options and after carefully
considering the risks and benefits of treatment, standard
ipilimumab was initiated at 3 mg/kg every three weeks
for four doses. During ipilimumab, he had no significant
irAEs and no exacerbation of his MS. He continued to
receive interferon beta treatment for his multiple scler-
osis while receiving ipilimumab. Unfortunately, after
completing ipilimumab, a positron emission tomography
(PET) scan showed progressive disease with worsening
widespread metastatic melanoma. Despite subsequent
treatment with carboplatin and paclitaxel, he died due to
melanoma progression in March 2013.
Case presentation 2
A 67-year-old woman presented to a rheumatologist
with anemia, weight loss, and multiple joint effusions.
Based upon clinical criteria as per the American College
of Rheumatology/European League Against Rheumatism
collaborative initiative [11], she was diagnosed with sero-
negative rheumatoid arthritis (RA) in 2007. She under-
went a left knee aspiration, showing 16,000 white blood
cells with neutrophil predominance. She was then startedon treatment with prednisone 20 mg daily and methotrex-
ate 15 mg weekly with significant improvement in her
symptoms.
Around this time, she was also diagnosed with cutane-
ous melanoma. She first noticed a pigmented lesion on
her right calf in 2005. Biopsy of the right leg lesion was
performed, with pathology revealing invasive melanoma,
0.72 mm in Breslow thickness, no ulceration was seen.
Local excision of the melanoma and right inguinal sentinel
lymph node biopsy one month later showed no residual
malignant melanoma.
Following initial surgical resection, the patient remained
without melanoma recurrence until November 2011 when
she noticed subcutaneous lesions in the left anterior neck
and right lower back. She underwent skin excisional
biopsy of the suspicious site on her right lower back
with pathology consistent with metastatic melanoma.
Molecular analysis revealed no apparent mutation in
BRAF, NRAS or KIT. Whole body PET/CT scan revealed
metastatic disease with multiple lung and subcutaneous
nodules.
Though ipilimumab was initially considered, it was
deferred out of concern it would exacerbate the patient’s
RA, which still required methotrexate and low-dose
corticosteroids for maintenance. Instead, the patient was
treated on a clinical trial involving a gamma secretase
inhibitor in combination with cisplatin, vinblastine, and
temozolomide (CVT) chemotherapy. Despite initial clinical
benefit with this regimen, melanoma progression was ob-
served eight months later. Given limited treatment options,
ipilimumab was pursued after a complete discussion of its
potential risks and benefits in the setting of known RA.
In October 2012, the patient was initiated on a course of
ipilimumab (3 mg/kg every three weeks for four doses).
After completing four doses of ipilimumab, subsequent
imaging showed partial response, with overall decreased
bilateral lung nodules, soft tissue and osseous involvement
(Figure 1). Following completion of ipilimumab, she did
note slightly increased bilateral knee pain consistent with
known osteoarthritis rather than RA, and this was effect-
ively treated with celecoxib. Throughout this course, the
patient was maintained on methotrexate 15 mg weekly
and low-dose prednisone (5 mg daily).
In January 2014, over one year since starting ipilimumab,
a computed tomography (CT) scan demonstrated slow pro-
gression of disease. Given the long initial response, ipilimu-
mab re-induction has been pursued, and she is currently
undergoing this treatment. She has had no worsening
symptoms related to RA throughout the remainder of
course to date.
Conclusions
We describe two patients with active autoimmune dis-
eases treated with ipilimumab for metastatic melanoma
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Figure 1 Timeline of treatment and demonstration of response. (a) Baseline chest CT scan prior to ipilimumab showed multiple subcutaneous,
intramuscular, and pulmonary nodules (largest nodule indicated by white arrow). (b) Two months after completion of four treatments with ipilimumab,
restaging PET scan showed decreased size of lung nodules, soft tissue and osseous involvement. (c) Repeat CT scan showed near radiographic
resolution of lung nodule. (d) Timeline of described events (not to scale).
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knowledge, this is the first description of patients with
active autoimmune diseases to have received ipilimu-
mab. Despite the known irAE profile of ipilimumab and
the theoretical concern that ipilimumab could exacerbate
an underlying autoimmune disorder, whether ipilimumab
truly exacerbates underlying autoimmune conditions re-
mains unknown.
The patient described in case 2 had benefit from ipili-
mumab. In this patient, the ongoing immune suppression
(corticosteroids and methotrexate) required to optimally
treat RA, did not preclude a response to ipilimumab. This
finding is consistent with other recently published cases
where patients benefited from ipilimumab, despite on-
going low-dose immunosuppression needed for prior solid
organ transplants [12]. There remains no published litera-
ture documenting that concurrent immunosuppressive
treatments eliminate the possibility of a favorable thera-
peutic outcome from ipilimumab, and the potential bene-
fit of ipilimumab in this context merits further study.
Notably, patient 1 was diagnosed with melanoma soon
after starting immunosuppression for MS. Patient 2
experienced a melanoma recurrence after initiation of
immunosuppression for RA. While initial immunosup-
pression and timing of melanoma may have been com-
pletely independent events and due to increased clinical
contact, it is theoretically possible that they were related
as has been previously described [13].
We recognize these are only two patient experiences,
and anecdotal experiences cannot be seen as definitive
evidence for the safety of immunotherapy in this setting.
The experiences with these two patients’ autoimmuneconditions may also not be generalizable to patients with
other autoimmune disorders, which may have different
underlying pathophysiology.
Nevertheless, these experiences advocate for further
evaluation of cancer immunotherapies for patients with
underlying autoimmune conditions. Professional societies
and patient advocacy groups may consider mechanisms
for patient registries, and carefully designed clinical trials
with cautious monitoring will help to increase our under-
standing of immunotherapies in this patient population.
This may become increasingly important as approaches
targeting the programmed cell death-1 (PD-1) receptor,
which is typically associated with minimal inflammatory
toxicity, expand in multiple malignancies. Such efforts will
help define the tenuous line between enhancing antitumor
immunity and avoiding exacerbation of an underlying
autoimmune disorder.Consent
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